{
  "clinicalQuestion": "",
  "picoP": "The diseases of interest are:  * PCa:    * MeSH terms and unique ID:      * Prostatic neoplasms: D011471.  The target populations are:  * Age: adult ≥18 years of age.  * PCa:    * Localized primary cancers (stage I or II) located in prostate:      * ICD-10: C61;      * Excluded: stage III: the radiation dose necessary to reach LC would be too high.",
  "picoI": "  * Tumor resection through stereotactic ablative body RT (SABR)/SBRT applied as:    * monotherapy (at any moment).    * combined with:      * ADT (PCa only);      * EBRT;      * IMRT;      * Volumetric-modulated arc therapy (VMAT);      * 3D-CRT;      * TACE (if providing relevant information);      * Image-guided RT (HIGRT).  * Not considered if SBRT was combined with the following drug interventions: chemotherapy, monoclonal antibodies or immunotherapy.  * Excluded interventions: spine stereotactic radiosurgery (SSRS)  * SBRT characteristics:    * SBRT understood as one–seven fraction schemes;    * if declared as SBRT in the study;    * Example of surgical risk definition: ‘high risk’ in lung means to be able to tolerate sublobar resection but not lobectomy;    * Simulators were not considered;    * Effects of complementary devices were not included.  * MeSH terms and unique ID: Radiosurgery, D016634    * Entry terms: stereotactic body radiotherapy, radiotherapy, stereotactic body, stereotactic body radiotherapies.  * Manufacturers: examples of possible CE-marked technologies that enable SBRT: accelerators, such as Tomotherapy, Varian Trilogy, Varian Unique, Varian ix, Varian True Beam, Varian Edge, Elekta Synergy-S, Elekta Axesse, Elekta Infinity, Elekta Versa HD or CyberKnife  ",
  "picoC": "* Only SoC therapies were considered for direct comparisons in each population subgroup using the following scheme:  * RT (MeSH term, D011878) such as:    * Conventional/standard (any RT between eight and any number of fractions);    * 3D-CRT;    * IMRT;      * MeSH terms and unique ID: radiotherapy, intensity-modulated, D050397;    * VMAT;      * MeSH terms and unique ID: radiotherapy, intensity-Modulated, D050397;  * Surgery (MeSH term and unique ID: general surgery, D011878; surgical procedure, operative, D013514);  * Surgery + conventional RT;  * AS (PCa):    * MeSH terms and unique ID: watchful waiting, D057832.Table of comparators scheme:| RT          | Surgery     | Surgery and conventional RT || ----------- | ----------- | --------------------------- || If operable | If operable | If operable                 |", 
  "picoO": "### EFF related  * Overall survival at 10 years;  * Local disease control;  * Distant disease recurrence/metastases;  * Treatment-associated mortality (survival);  * Number and percentage of patients with LC;  * Biochemical control (biochemical recurrence free survival);  * QoL(SF-36/EPIC);  * Percentage of patients with ADT because of recurrence;  * Change in EPIC QoL questionnaire;  * Urinary or bowel symptoms (EPIC-26 questionnaire or separately);  * Changes in a pain scale.    ### SAF related  * Major surgical complications (presence or absence of Grade >2 AE);  * Acute urinary and digestive toxicity (RTOG-EORTC/CTCAE scales);  * Late urinary and digestive toxicity (RTOG-EORTC/CTCAE scales)."
}
